Beijing Scitech-MQ Pharmaceuticals identifies RIPK1 inhibitors for cancer
Aug. 3, 2023
Beijing Scitech-MQ Pharmaceuticals Ltd. described receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of cancer.